Dr. Michael Har-Noy Indicates That We Are Losing The War Against Cancer

30 Mar

“We are losing the fight against cancer” says Dr. Michael Har-Noy, CEO of Immunovative Therapies, a young biotech firm started in Israel in 2004. Dr. Michael Har-Noy indicates that in past 30 years, the incidence of cancer has increased dramatically, affecting almost one out of every three females and one out of every two males.. This means that the current rate of cancer is 50% higher in men and 25% higher in women than in the past generation. The National Cancer Institute predicts that, because of our growing elderly population, the number of cancer cases will virtually double by the year 2050.

Dr. Michael Har-Noy says that in spite of years of clinical trials and research, decreases in overall mortality from cancer have been minimal, and noted reductions in death rates are largely due to decreases in lung cancer deaths secondary to a lower incidence of smoking, and not from true breakthroughs in cancer treatment. Also, Dr. Michael Har-Noy says that the total five-year survival rate of about 50% for all cancer cell types is almost identical to what it was in 1970.

Conventional cancer therapies have devastating emotional and physical effects. Many patients feel that the treatment is worse than the disease. The financial burden that cancer treatment places on society is also staggering.  Dr. Michael Har-Noy notes that the approximate direct annual cost of cancer therapy has quadrupled over the past 2 decades. It has ballooned from about $18 billion in 1985 to $41 billion in 1995, and then to a gigantic $80 billion in 2005. Dr. Michael Har-Noy notes that indirect costs from wage losses, tax increases, and decreases in overall productivity secondary to cancer was a staggering $100 billion in 1999.

At Immunovative Therapies, Ltd., Dr. Michael Har-Noy creates novel biologic treatments that stimulate one’s own immune system to attack cancer cells. Initial results of a Phase I/II trial show amazing efficacy of these drugs across a wide range of tumors. Definitive randomized Phase II/III trials of these new treatments are in the works.


%d bloggers like this: